Diabetologia

, Volume 35, Issue 1, pp 96–97 | Cite as

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

  • D. Edelstein
  • M. Brownlee
Rapid Communication

Summary

We studied the effect of aminoguanidine, an inhibitor of advanced glycation product formation, on albuminuria in chronically diabetic spontaneously hypertensive rats. At the time of killing, there was no statistically significant difference in blood glucose concentration between the treated and untreated diabetic animals (18.2±0.69 mmol/l), nor was there any difference among the non-diabetic, diabetic untreated, and diabetic treated rats with respect to blood pressure (169±6.9 mm Hg). However, non-diabetic hypertensive animals had a mean quantitative 24-h urinary albumin excretion of 28±2 mg albumin/24-h, while untreated diabetic hypertensive animals averaged nearly four times that amount (106 ±3 mg albumin/24 h). Without affecting blood pressure, aminoguanidine treatment of diabetic hypertensive animals decreased the diabetic-associated elevation in urinary albumin excretion by 75% (48±2 mg/24 h). These data suggest than inhibition of advanced glycation product formation ameliorates the glomerular dysfunction caused by chronic hyperglycaemia.

Key words

Nephropathy diabetes aminoguanidine glycation hypertension 

References

  1. 1.
    Krolewski AS, Warram JH, Christleib AR et al. (1985) The changing natural history of nephropathy in type 1 diabetes. Am J Med 78: 785–794Google Scholar
  2. 2.
    Brownlee M, Sherwood LM (1990) Diabetes mellitus and its complications: pathogenesis and treatment. Hanley & Belfus, PhiladelphiaGoogle Scholar
  3. 3.
    Berkman J, Rifkin H (1973) Unilateral nodular diabetic glomerulosclerosis. Metabolism 22: 715–722Google Scholar
  4. 4.
    Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen Paa (1987) Effect of anti-hypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294: 1443–1447Google Scholar
  5. 5.
    Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629–1632Google Scholar
  6. 6.
    Fein FS, Zola BE, Malhotra A, Cho S, Factor SM, Scheuer J (1990) Hypertensive-diabetic cardiomyopathy in rats. Am J Physiol 258: H793–805Google Scholar
  7. 7.
    Nicholls K, Mandel TE (1989) Advanced glycosylation endproducts in experimental murine diabetic nephropathy. Lab Invest 60: 486–493Google Scholar
  8. 8.
    Ellis EN, Bowen W (1990) Aminoguanidine ameliorates glomerular basement membrane thickening in experimental diabetes. Diabetes 39 [Suppl 1]: 71A (Abstract)Google Scholar
  9. 9.
    Kihara M, Schmelzer JD, Poduslo JF, Curran FF, Nickander KK, Low PA (1991) Aminoguanidine effect on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88: 6107–6111Google Scholar
  10. 10.
    Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315–1321Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • D. Edelstein
    • 1
  • M. Brownlee
    • 1
  1. 1.Diabetes Research Center and Departments of Medicine and PathologyAlbert Einstein College of MedicineBronxUSA

Personalised recommendations